Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Medical expertise
Food and Drug Administration (2023) Efficacy of semaglutide in a subcutaneous and an oral formulation, Frontiers in Endocrinology (2021) Glucagon-like peptide-1 receptor agonists for chronic weight management, Advances in Medicine (2023) Ozempic drug label information, DailyMed (2023) Rybelsus drug label information, DailyMed (2022) Low blood glucose (hypoglycemia), National Institute of Diabetes and Digestive and Kidney Diseases (2021) Cancer of the thyroid, American Thyroid Association Acute kidney injury (AKI), National Kidney Foundation What happens when a drug goes viral?, Harvard Health (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Cut-through view showing that the GLP-1 peptide N-terminal H7 (orange ball and stick) reaches the same level as the orthosteric agonist BI-167107 (yellow)
A missed dose is skipped instead of doubled
A total of 19.7% of the participants in the tirzepatide group had a reduction in body weight of at least 30% (an exploratory end point) as compared with 6.9% of those in the semaglutide group, which indicated that the likelihood of meeting this weight-reduction target with tirzepatide was 2.8 times as high as that with semaglutide
US$ 27.75
US$ 23.56
US$ 29.90
US$ 25.09
